
Altimmune, Inc.
Altimmune, Inc. (ALT)
WebsitePrice
Market cap
Next catalystFDA End-of-Phase 2 meeting for the AUD programme — December 2026pemvidutide (ALT-801) — RECLAIM · Regulatory meetingSEC filing ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved